Navigation Links
Mechanism for the in-vivo transport of siRNA
Date:9/22/2007

le of being bonded to other lipophilic substances in addition to cholesterol, and caused a reduction in the activity of a target gene in the liver at the same time. It turned out that there are several such fatty acids. But what is it in the blood to which all these RNAs conjugated with so-called lipophilic substances bond" The ETH Zurich researchers discovered that, depending on the fatty acid used, the binding partners are the well-known cholesterol transporters High Density Lipoproteins (HDL) and Low Density Lipoproteins (LDL) as well as the albumin (protein) present everywhere in the blood. Without these lipoprotein particles there is no uptake of siRNAs into the tissues, as became apparent from further experiments. In an additional experiment the scientists demonstrated that the uptake can be made considerably more efficient if the siRNA-fatty acid molecules are already firmly bonded to HDL and LDL before being administered. Stoffels team also discovered that there is preferential uptake into different tissues depending on whether an siRNA-fatty acid molecule is bonded to HDL or LDL: all LDL compounds trigger responses in the liver, but HDL compounds also do so in the intestine or kidneys.

An irritating finding

The latter finding indicated that the uptake proceeds via HDL and LDL receptors. The researchers proved this assumption by inactivating the receptors, with the result that uptake no longer occurred. Despite the clarity of the finding, it irritated Stoffel slightly. He found it hard to imagine that the siRNAs were able to enter the cell via the normal absorption route like HDL, because this route leads into the cells own digestive system with lysosomes that would degrade the siRNAs. So how would the siRNAs be able to avoid this degradation" Stoffel concluded that they simply use a different doorway into the cell. Thus the HDL and LDL receptors would only act as docking stations but not as an entry portal.

But what might t
'/>"/>

Contact: Professor Marcus Stoffel
41-446-334-560
Swiss Federal Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology technology :

1. Confirming gene silencing mechanism by pGFP/GFP22 siRNA co-transfection
2. Polymer Degradation Mechanisms Encountered in Pyrolysis-GC/MS
3. Could Tommy Thompsons next stop be Transportation, Homeland Security, or the private sector?
4. Custom and library siRNA for efficient gene silencing
5. Custom and library siRNA for efficient gene silencing
6. Cancer siRNA Oligo Set Version 1.0
7. Library siRNA
8. Custom siRNA Oligo Synthesis Service
9. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
10. Quantification of siRNA Silencing Efficiency Using the LightCycler System
11. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Newly discovered mechanism allows cells to change state 2More than fish bait: Worms unlock secrets to new epilepsy treatments 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 2ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 3ORAL COTI-2 IS EFFECTIVE IN AN ANIMAL MODEL OF HUMAN PANCREATIC CANCER 4PDL BioPharma to Present at Oppenheimer 26amp 3B Co 20th Annual Healthcare Conference on November 4 2009 14619 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 1Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 2Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 3Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 4Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 5Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 6Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 7Endologix Reports 47 25 Third Quarter 2009 Revenue Growth 5765 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 1Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 2Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 3Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 4Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 5Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 6Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 7Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 8Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 9Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 10Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 11Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 12Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 13Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 14Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 15Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 16Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 17Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 18Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 19Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 20Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 21Cephalon Net Sales Increase 9 25 and Net Cash from Operations Surpasses 24200 Million in the Third Quarter 2009 5760 22